**Highlights of This Issue**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1841</td>
<td>First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer</td>
<td>Leyre Brizuela, Isabelle Ader, Catherine Mazerolles, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier</td>
</tr>
<tr>
<td>1852</td>
<td>Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters</td>
<td>KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe</td>
</tr>
<tr>
<td>1873</td>
<td>Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets</td>
<td>Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar</td>
</tr>
<tr>
<td>1884</td>
<td>Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo</td>
<td>Livio Mailucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha</td>
</tr>
</tbody>
</table>

**Preclinical Development**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1936</td>
<td>Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts</td>
<td>Muralidharan Anbalagan, Alaa Ali, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan</td>
</tr>
</tbody>
</table>
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Liewehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg

Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguilar, Yuri Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angeline S. Andrew, Vincent Memoli, and Ethan Dmitrovsky

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Ana Vivancos, and Josep Tabernero

Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Yoko Matsuda, Masahito Hagio, Tomoko Seya, and Toshiyuki Ishiwata

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Pierre Saintigny, Shaohua Peng, Li Zhang, Banibhata Sen, Ian G. Wistuba, Scott M. Lippman, Luc Girard, John D. Minna, John V. Heymach, and Faye M. Johnson

The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is A Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
Rupashree Sen, Karthika Natarajan, Jaspreet Bhullar, Sunet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
Judy Quiju Shi, Keri Lasky, Vanshali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe Nestor, Benjamin S. Amidon, Yousan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’ Amore, and Marc L. Hyer

Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility
Dana Ziliak, Eric R. Gamazon, Bonnie LaCroix, Hye Kyung Im, Yujia Wen, and Rong Stephanie Huang

MOLECULAR MEDICINE IN PRACTICE

Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarrull, Elena Elez, Maria Alsina, Jaume Capdevila, Jose Perez-Garcia, Gessami Sanchez-Orill, Claudia Aura, Ludmila Frudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero

Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors
Kali M. Leith, Ph.D., Telford A. Green, Cameron V. Gray, Brenda J. Tapp, Helmi J. El-Serag, and Miriam J. Povirk
Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.